Veradermics Q3 2026 net loss widens to $21.0 million; cash totals $798.4 million
Veradermics reported results for the quarter ended September 30, 2026, with a net loss of $21.0 million, up from $20.1 million a year earlier, as general and administrative expenses rose to $12.7 million from $2.3 million. The company ended the quarter with $798.4 million in cash, cash equivalents and marketable securities, which it says should fund operations into 2030. For shareholders, the larger loss and higher overhead weigh against the positive clinical updates, and the filing reports no revenue for the quarter.
Key points
- Q3 2026 net loss was $21.0 million, compared with $20.1 million in Q3 2025; nine-month net loss was $71.7 million versus $48.1 million.
- G&A expenses rose to $12.7 million from $2.3 million, driven by payroll, stock-based compensation and commercial readiness costs.
- R&D expenses fell to $16.1 million from $18.1 million; cash stood at $798.4 million on September 30, 2026, up from $141.9 million at December 31, 2025.
- Topline data from Phase 2/3 Study '306' in female pattern hair loss is expected in the first half of 2027.
The filing
Written by AI on Nov 10, 2026, 9:03 AM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.